Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

POZEN Inc. POZN NASDAQ

NASDAQ • Healthcare • Medical - Pharmaceuticals • US • USD

SharesGrow Score
78/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

POZEN Inc. (POZN) is a Medical - Pharmaceuticals company in the Healthcare sector, currently trading at $5.94. It has a SharesGrow Score of 76/100, indicating a strong investment profile with 3 out of 7 criteria passed.

Financials: revenue is $32M, +71%/yr average growth. Net income is $20M, growing at +30.7%/yr. Net profit margin is 60.7% (strong). Gross margin is 100% (+82.7 pp trend).

Balance sheet: total debt is $254M against $47M equity (Debt-to-Equity (D/E) ratio 5.43, leveraged). Current ratio is 13.32 (strong liquidity). Debt-to-assets is 502.7%. Total assets: $50M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 50/100 (Partial), Health 67/100 (Partial), Moat 50/100 (Partial), Future ?/100 (Fail), Income 100/100 (Pass).

POZN SharesGrow Score Overview

78/100
SharesGrow Score
Strong investment profile
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 50/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 100/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — POZN

✓
VALUE Pass
100/100
POZN trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
POZN: +71%/yr revenue is, +30.7%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
~
PAST Partial
50/100
POZN: 2 / 4 years profitable. weak. Score = 2 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
67/100
Balance sheet POZN: Debt-to-Equity (D/E) ratio 5.43 (leveraged), Current ratio is 13.32 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
POZN: Gross margin is 100% (+82.7 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✓
INCOME Pass
100/100
POZN: Net profit margin is 60.7%. strong (≥30%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range12.69-5.49
Volume1.38M
Avg Volume (30D)481.23K
Beta (1Y)2.16
Share Statistics
EPS (TTM)0.63
Shares Outstanding$31.36M
IPO Date2016-01-04
Financial Highlights & Ratios
Revenue (TTM)$32.39M
Gross Profit$32.39M
EBITDA$19.69M
Net Income$19.68M
Operating Income$19.68M
Total Cash$43.26M
Total Debt$253.62M
Net Debt$213.04M
Total Assets$50.45M
Price / Earnings (P/E)9.4
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ
CurrencyUSD

Price Chart

Track all markets on TradingView
POZN
POZEN Inc.  ·  NASDAQ
Healthcare • Medical - Pharmaceuticals

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message